Bayer sees 2026 adj. EBITDA EUR9.6B to EUR10.1B, est. EUR9.75B

Bayer sees 2026 adj. EBITDA EUR9.6B to EUR10.1B, est. EUR9.75B

Bayer AG’s 2026 Adjusted EBITDA Forecast and Credit Outlook

Bayer AG has projected its 2026 adjusted EBITDA to range between €9.6 billion and €10.1 billion, with analysts estimating approximately €9.75 billion at the midpoint. This forecast reflects the company’s strategic focus on cost optimization and performance in its core agricultural and pharmaceutical segments amid ongoing market challenges.

Recent credit rating developments, however, highlight lingering concerns. Both S&P Global and Fitch Ratings have revised Bayer’s credit outlook to negative, while maintaining its issuer credit rating (IDR) at ‘BBB’. S&P cited "increased uncertainty" surrounding Bayer's financial resilience, particularly regarding litigation risks and margin pressures in its Crop Science division according to their analysis. Fitch echoed similar sentiments, noting that while the company's liquidity remains adequate, structural challenges—such as regulatory headwinds and R&D costs in pharmaceuticals—could pressure long-term stability as reported.

The negative outlook signals that downgrades may occur if Bayer fails to meet financial targets or if external risks escalate. For instance, unresolved litigation related to Roundup herbicides and potential delays in key drug approvals could impact cash flows and profitability. Conversely, successful execution of cost-saving initiatives and growth in high-margin pharmaceutical products may mitigate these risks.

Investors should monitor Bayer's ability to navigate these dynamics. While the 2026 EBITDA guidance suggests operational improvements, the credit agencies' caution underscores the importance of risk management. A downgrade could increase borrowing costs and heighten investor scrutiny, particularly as Bayer balances debt reduction with innovation investments.

In summary, Bayer's near-term financial outlook appears stable, but structural challenges warrant careful oversight. Stakeholders are advised to track litigation developments, R&D progress, and regional market performance to assess the sustainability of its financial trajectory.

Source: S&P Global Ratings
Source: Fitch Ratings
Source: Fitch Ratings